Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Stopped The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

Conditions

• NSCLC (Non-small Cell Lung Carcinoma)

Interventions

• DRUG: Ruxolitinib
• DRUG: Placebo
• DRUG: Pemetrexed
• DRUG: Cisplatin

Sponsor

Incyte Corporation